Glanbia Plc · EURONEXT:GL9
Glanbia — Q3 2023 Earnings Presentation
12 slides from Glanbia's earnings presentation, Nov 1, 2023
Slide 1: Glanbia plc Q3 2023 Interim Management Statement Presentation
Glanbia plc Q3 2023 Interim Management Statement Presentation 1 November 2023 Siobhán Talbot Mark Garvey Group Managing Director Group Finance Director
Slide 2: Important notice
Important notice This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both economic and busi
Slide 3: Q3 2023 Highlights
Q3 2023 Highlights Group’s portfolio of better nutrition brands and ingredients continues to resonate strongly with consumers seeking health and wellness GPN consumption trends continue to be good across the performance nutrition and healthy lifestyle brand portfolios GN NS volume trajectory improvi
Slide 4: YTD Q3 2023 Revenue overview
YTD Q3 2023 Revenue overview GPN LFL* branded revenue growth +3.0% led by Optimum Nutrition brand GN revenue decline primarily related to dairy market pricing, volume trends improving as year progressing Revenue Growth (Constant Currency) Acquisitions Volume Price LFL* Total / Disposals BRANDED -5.9
Slide 5: GPN – YTD Q3 2023 performance
GPN – YTD Q3 2023 performance YTD Q3 2023 GPN Revenue Mix % LFL* Branded Revenue Growth +3.0% Volume -5.9% 18% Price +8.9% 61% • LFL revenue -1.8% in Americas and +12.3% in International 10% • Good demand trends in ON and healthy lifestyle with volume decline driven by SlimFast Portfolio brands • Pr
Slide 6: Leading brands in performance and lifestyle nutrition
Leading brands in performance and lifestyle nutrition Strong revenue and consumption momentum continues in ON and healthy lifestyle Performance Healthy Weight Nutrition Lifestyle Management % of GPN Revenue 61% 18% 10% LFL growth* +14.5% +7.2% -33.9% US Consumption** +9.5% +12.3% -35.8% GLANBIA PLC
Slide 7: GN NS – YTD Q3 2023 performance
GN NS – YTD FY 2022 Q3 2023 performance performance Revenue Growth* -17.2% LFL Volume by Quarter Volume -6.4% Price -7.6% Volume growth in third quarter following period of Acquisitions / Disposals -3.2% supply chain rebalancing in the first half of 2023 • Volume growth in the third quarter driven b
Slide 8: Q3 2023 Finance review
Q3 2023 Finance review Mark Garvey Group Finance Director 8
Slide 9: YTD Q3 2023 Strong Balance Sheet
YTD Q3 2023 Strong Balance Sheet Net debt $334.9m Completed the FY 2023 expected to be €100m returned in share acquisition of the B2B $75m - $85m buybacks in YTD 2023 bioactive ingredients Total committed facilities business of PanTheryx of $1.3 billion for $46m GLANBIA PLC | Q3 2023 IMS PRESENTATIO
Slide 10: FY 2023 Guidance
FY 2023 Guidance Lead & grow Optimise our Disciplined our core business financial management Organic revenue growth Margin & earnings growth Capital allocation GPN LFL revenue growth: GPN EBITA margin: OCF conversion %: approximately 5% 14.0% to 14.5% 80% to 90% GN NS volume: GN NS EBITA margin: ROC
Slide 11: Glanbia: At the Heart of Better Nutrition
Glanbia: At the Heart of Better Nutrition Strong FY 2023 Group earnings and margin progression expected, driven by GPN Upgrading full year guidance to 17% to 20% growth in adjusted EPS, constant currency 2023 – 2025 strategy on track Consumer opportunity for the Group’s portfolio of better nutrition
Slide 12: Questions?
Questions?